^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

methylprednisolone sodium succinate

i
Other names: NPB-01-ME, NPB01ME, NPB 01 ME
Associations
Company:
Generic mfg.
Drug class:
GCR agonist
Associations
7d
Case Report: From metabolic normalization to incidental type A aortic dissection in immune checkpoint inhibitor-associated aortitis. (PubMed, Front Oncol)
A 58-year-old man with KRAS-G12C-mutated stage IVB lung adenocarcinoma initiated first-line treatment with carboplatin + pemetrexed + pembrolizumab...Intravenous methylprednisolone led to rapid defervescence and biochemical improvement...Thereafter, he initiated adagrasib, achieving a durable partial response. This case illustrates discordance between metabolic quiescence and later structural damage in immune checkpoint inhibitor-associated aortitis. This supports long-term structural surveillance, as 18F-FDG PET/CT normalization does not guarantee structural safety.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed • Krazati (adagrasib) • methylprednisolone sodium succinate
14d
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (clinicaltrials.gov)
P1/2, N=10, Terminated, Masonic Cancer Center, University of Minnesota | N=55 --> 10 | Trial completion date: Sep 2028 --> Feb 2026 | Suspended --> Terminated | Trial primary completion date: Sep 2026 --> Feb 2026; Sponsor terminated financial support
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
Jakafi (ruxolitinib) • prednisone • methylprednisolone sodium succinate
22d
New trial
|
methylprednisolone sodium succinate
26d
ETA/PETA-NMOSD: Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (clinicaltrials.gov)
P4, N=200, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jun 2029 | Trial primary completion date: Jun 2026 --> Jun 2027
Enrollment open • Trial completion date • Trial primary completion date • Real-world evidence
|
methylprednisolone sodium succinate
27d
Enrollment open
|
prednisone • sirolimus • methylprednisolone sodium succinate
28d
New P2 trial
|
CRP (C-reactive protein)
|
methylprednisolone sodium succinate
1m
Trial completion date • Trial primary completion date
|
Gazyva (obinutuzumab) • prednisone • methylprednisolone sodium succinate
1m
Efficacy of Nerve Blocks for Episodic Migraine (clinicaltrials.gov)
P2, N=60, Recruiting, Mayo Clinic | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
Trial completion date • Trial primary completion date
|
methylprednisolone sodium succinate
1m
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (clinicaltrials.gov)
P1/2, N=55, Suspended, Masonic Cancer Center, University of Minnesota | Recruiting --> Suspended
Trial suspension
|
Jakafi (ruxolitinib) • prednisone • methylprednisolone sodium succinate
1m
Vitamin C With Steroids for Gastrointestinal GVHD (clinicaltrials.gov)
P1, N=35, Not yet recruiting, Baylor College of Medicine | Initiation date: Jan 2026 --> Jun 2026
Trial initiation date
|
methylprednisolone sodium succinate
1m
Rapidly Progressive Overlap of Immune Checkpoint Inhibitor-Induced Myositis and Myasthenia Gravis: Diagnostic and Therapeutic Challenges. (PubMed, Cureus)
We report a fulminant case of overlap syndrome involving ICI-induced myositis and myasthenia gravis in a 72-year-old man receiving ipilimumab-nivolumab for hepatocellular carcinoma and recurrent renal cell carcinoma...Despite prompt intensive care admission and treatment with high-dose intravenous methylprednisolone and intravenous immunoglobulin, only partial clinical improvement was achieved. The subsequent development of aspiration pneumonia led to acute respiratory and hepatic failure, culminating in death. This case underscores the aggressive clinical trajectory and high mortality of ICI-related neuromuscular overlap syndromes, highlighting the critical need for early recognition, rapid immunosuppression, and multidisciplinary management.
Journal • Checkpoint inhibition
|
MB (Myoglobin)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • methylprednisolone sodium succinate
1m
EXAFIP2: Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov)
P3, N=110, Recruiting, Fondation Hôpital Saint-Joseph | Trial primary completion date: Oct 2025 --> Mar 2026
Trial primary completion date
|
prednisone • methylprednisolone sodium succinate